Company news

Capricor Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress

October 5, 2026

Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress

September 17, 2026

SHAREHOLDER REMINDER: Berger Montague Reminds Capricor Therapeutics, Inc. (CAPR) Investors of the September 28, 2026 Deadline

September 11, 2026

Pomerantz LLP Issues Reminder to Investors in Capricor Therapeutics, Inc. of Class Action Filing - CAPR

August 26, 2026

Capricor Therapeutics, Inc. (CAPR) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before September 28, 2026 Lead Plaintiff Deadline

August 25, 2026

Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA

August 24, 2026

Capricor Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Capricor Therapeutics, Inc. - CAPR

August 21, 2026

Pomerantz LLP Alerts Shareholders to Investor Suit Against Capricor Therapeutics, Inc. - CAPR

August 17, 2026

Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 13, 2026

Capricor Therapeutics, Inc. (CAPR) Securities Fraud Investigation - Levi & Korsinsky

August 3, 2026

CAPR SHAREHOLDER INVESTIGATION: Levi & Korsinsky Investigates Capricor Therapeutics, Inc. for Possible Securities Law Violations

August 2, 2026

CAPR Investor Alert: Levi & Korsinsky Investigates Capricor Therapeutics, Inc. (CAPR) for Potential Securities Fraud

August 1, 2026

Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel

July 30, 2026

CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Investigation Opened Following Massive Stock Crash

July 29, 2026

The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy

July 29, 2026

Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

June 26, 2026

Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference

June 26, 2026

Capricor Therapeutics Expands Commercial Leadership Team

May 28, 2026

Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 12, 2026

Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12

May 4, 2026

Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting

April 22, 2026

Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

March 12, 2026

Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy

March 11, 2026

Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA

March 9, 2026

Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12

March 8, 2026

Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference

February 23, 2026

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Atkore Inc. (ATKR), Axsome Therapeutics, Inc. (AXSM), Capricor Therapeutics, Inc. (CAPR), and CTO Realty Growth, Inc. (CTO)

February 5, 2026

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data

January 20, 2026

Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy

December 16, 2025

Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock

December 5, 2025

Capricor Therapeutics Announces Proposed Public Offering of Common Stock

December 4, 2025

Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy

December 3, 2025

Capricor Therapeutics Presents New Data Demonstrating a Scalable Framework for Loading Therapeutic Oligonucleotides into Exosomes at AAEV 2025

November 24, 2025

Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 10, 2025

Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation

November 4, 2025

Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel

November 3, 2025

Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10

October 31, 2025

Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting

September 25, 2025

Shareholders of Capricor Therapeutics, Inc. Should Contact The Gross Law Firm Before September 15, 2025 to Discuss Your Rights - CAPR

September 15, 2025

Lost Money on Capricor Therapeutics, Inc. (CAPR)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

September 15, 2025

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before September 15, 2025 to Discuss Your Rights - CAPR

September 15, 2025

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR

September 15, 2025

Securities Lawsuit Alert: Capricor Therapeutics, Inc. (CAPR) - Contact Levi & Korsinsky Before September 15, 2025

September 9, 2025

Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel

September 9, 2025

Shareholders of Capricor Therapeutics, Inc. Should Contact Levi & Korsinsky Before September 15, 2025 to Discuss Your Rights - CAPR

September 8, 2025

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 15, 2025 to Discuss Your Rights - CAPR

September 5, 2025

September 15, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against CAPR

September 5, 2025

Join Class Action to Recover Losses from Capricor Therapeutics, Inc. (CAPR) - Contact Levi & Korsinsky Before September 15, 2025

September 4, 2025

Investors in Capricor Therapeutics, Inc. (CAPR): Protect Your Rights - Contact Levi & Korsinsky Before September 15, 2025

August 28, 2025

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - CAPR

August 28, 2025

Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 38 decks. Every deck is listed under its year.